1. Scrip

AstraZeneca Moves Into Obesity With Eye On Combinations

 
• By Jessica Merrill

The company licensed an oral GLP-1 agonist from Eccogene, hoping to capitalize on its heritage in cardiovascular disease. AstraZeneca also reported third quarter results.

combination drugs
AstraZeneca is interested in developing combination drugs in obesity • Source: Shutterstock

AstraZeneca PLC is hoping to claim a piece of the obesity market, believing its cardiovascular, renal and metabolism (CVRM) strength will be an advantage, despite being well behind rivals. The company announced a licensing deal with Eccogene (Shanghai) Co., Ltd for an oral glucagon-like peptide 1 (GLP-1) receptor agonist for the treatment of obesity, type 2 diabetes and other cardiometabolic conditions on 9 November, coinciding with its third quarter sales and earnings announcement.

Key Takeaways
  • AstraZeneca is in-licensing an oral GLP-1 agonist for the treatment of obesity, type 2 diabetes and other cardiometabolic conditions from Eccogene.

“We truly believe there is a unique opportunity, not only to help patients to lose weight but also to help...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.